Symbicort Turbuhaler 30/60 Clinical Experience Investigation for Treatment With Symbicort as Maintenance Therapy and as Needed in Response to Symptoms

AstraZeneca1 site in 1 country2,409 target enrollmentNovember 2012

ConditionsBronchial Asthma

Overview

Phase: N/A
Intervention: Not specified
Conditions: Bronchial Asthma
Sponsor: AstraZeneca
Enrollment: 2409
Locations: 1
Primary Endpoint: Adverse event incidence
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.

Detailed Description

Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms

Registry

clinicaltrials.gov

Start Date

November 2012

End Date

August 2015

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients receiving Symbicort Turbuhaler as maintenance and reliever therapy for the first time due to 'bronchial asthma ',and possibly requiring as-needed inhalations during the observation period